AZ-11713908 explained

AZ-11713908 is a drug developed by AstraZeneca which is a peripherally selective cannabinoid agonist, acting as a potent agonist at the CB₁ receptor and a partial agonist at CB₂. It has poor blood–brain barrier penetration, and so while it is an effective analgesic in animal tests, it produces only peripheral effects at low doses, with much weaker symptoms of central effects compared to other cannabinoid drugs such as WIN 55,212-2.^[1] Many related benzimidazole-derived cannabinoid ligands are known.^{[2] [3]}

See also

• AM-6545
• AZD-1940
• CB-13
• RQ-00202730

References

1. Yu XH, Cao CQ, Martino G, Puma C, Morinville A, St-Onge S, Lessard E, Perkins MN, Laird JM . A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain . Pain . 151 . 2 . 337–44 . November 2010 . 20696525 . 10.1016/j.pain.2010.07.019 . 27731273 .
2. Verbist BM, De Cleyn MA, Surkyn M, Fraiponts E, Aerssens J, Nijsen MJ, Gijsen HJ . 5-Sulfonyl-benzimidazoles as selective CB2 agonists . Bioorganic & Medicinal Chemistry Letters . 18 . 8 . 2574–9 . April 2008 . 18394887 . 10.1016/j.bmcl.2008.03.048 .
3. Pagé D, Balaux E, Boisvert L, Liu Z, Milburn C, Tremblay M, Wei Z, Woo S, Luo X, Cheng YX, Yang H, Srivastava S, Zhou F, Brown W, Tomaszewski M, Walpole C, Hodzic L, St-Onge S, Godbout C, Salois D, Payza K, Payza K . Novel benzimidazole derivatives as selective CB2 agonists . Bioorganic & Medicinal Chemistry Letters . 18 . 13 . 3695–700 . July 2008 . 18522867 . 10.1016/j.bmcl.2008.05.073 .